A citation-based method for searching scientific literature

Christoph Wanner, John M Lachin, Silvio E Inzucchi, David Fitchett, Michaela Mattheus, Jyothis George, Hans J Woerle, Uli C Broedl, Maximilian von Eynatten, Bernard Zinman. Circulation 2018
Times Cited: 212



Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
Times Cited: 1574




List of shared articles



Times cited

A Pilot Study Embedding Clinical Pharmacists Within an Interprofessional Nephrology Clinic for the Initiation and Monitoring of Empagliflozin in Diabetic Kidney Disease.
Laura K Triantafylidis, Chelsea E Hawley, Christopher Fagbote, Jiahua Li, Nicole Genovese, Julie M Paik. J Pharm Pract 2021
4

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
75

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Cordula Zeller, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr,[...]. Circulation 2021
27

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
Bettina J Kraus, Matthew R Weir, George L Bakris, Michaela Mattheus, David Z I Cherney, Naveed Sattar, Hiddo J L Heerspink, Ivana Ritter, Maximilian von Eynatten, Bernard Zinman,[...]. Kidney Int 2021
8

Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Subodh Verma, C David Mazer, Silvio E Inzucchi, Christoph Wanner, Anne Pernille Ofstad, Odd Erik Johansen, Isabella Zwiener, Jyothis T George, Javed Butler, Bernard Zinman. Diabetes Obes Metab 2021
3


Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter,[...]. JAMA Cardiol 2021
0

CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS.
Gianluigi Savarese, Javed Butler, Lars H Lund, Deepak L Bhatt, Stefan D Anker. Cardiovasc Res 2021
0

Novel Therapies for Kidney Disease in People with Diabetes.
Nayana Khurana, Steven James, Melinda T Coughlan, Richard J MacIsaac, Elif I Ekinci. J Clin Endocrinol Metab 2021
0



Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
Samuel Dagogo-Jack, Richard E Pratley, David Z I Cherney, Darren K McGuire, Francesco Cosentino, Weichung J Shih, Jie Liu, Robert Frederich, James P Mancuso, Annaswamy Raji,[...]. BMJ Open Diabetes Res Care 2021
0


Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Silvio E Inzucchi, David Fitchett, Dubravka Jurišić-Eržen, Vincent Woo, Stefan Hantel, Christina Janista, Stefan Kaspers, Jyothis T George, Bernard Zinman. Diabetes Obes Metab 2020
31


Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Clare Arnott, Qiang Li, Amy Kang, Brendon L Neuen, Severine Bompoint, Carolyn S P Lam, Anthony Rodgers, Kenneth W Mahaffey, Christopher P Cannon, Vlado Perkovic,[...]. J Am Heart Assoc 2020
72



Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
Claire C J Dekkers, Ron T Gansevoort. Nephrol Dial Transplant 2020
18






Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S Aronow, William H Frishman. Cardiol Rev 2020
3

An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
3

Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice.
Ting Cai, Qingqing Ke, Yi Fang, Ping Wen, Hanzhi Chen, Qi Yuan, Jing Luo, Yu Zhang, Qi Sun, Yunhui Lv,[...]. Cell Death Dis 2020
12

Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials.
Api Chewcharat, Kullaya Takkavatakarn, Suramath Isaranuwatchai, Pisut Katavetin, Kearkiat Praditpornsilpa, Somchai Eiam-Ong, Paweena Susantitaphong. Int Urol Nephrol 2020
0

Microvascular disease in chronic kidney disease: the base of the iceberg in cardiovascular comorbidity.
Uwe Querfeld, Robert H Mak, Axel Radlach Pries. Clin Sci (Lond) 2020
7

Pleiotropic effects of anti-diabetic drugs: A comprehensive review.
Moumita Nath, Kasturi Bhattacharjee, Yashmin Choudhury. Eur J Pharmacol 2020
3

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes.
Oliver Schnell, Paul Valensi, Eberhard Standl, Antonio Ceriello. Endocrinol Diabetes Metab 2020
2

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Christoph Wanner, Silvio E Inzucchi, Bernard Zinman, Audrey Koitka-Weber, Michaela Mattheus, Jyothis T George, Maximilian von Eynatten, Sibylle J Hauske. Diabetes Obes Metab 2020
5

SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies.
Mei Qiu, Liang-Liang Ding, Miao Zhang, Jin-Hao Lin, Jin-Song Gu, Xian Zhou, Ying-Xi Tang, Xu-Bin Wei, Shu-Yan Liu. Pharmacol Res 2020
3

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.
Vikas S Sridhar, Lisa Dubrofsky, Jacinthe Boulet, David Z Cherney. J Bras Nefrol 2020
2

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association.
Janani Rangaswami, Vivek Bhalla, Ian H de Boer, Alexander Staruschenko, Johanna A Sharp, Radhika Rajgopal Singh, Kevin Bryan Lo, Katherine Tuttle, Muthiah Vaduganathan, Hector Ventura,[...]. Circulation 2020
25

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.
Adeera Levin, Vlado Perkovic, David C Wheeler, Stefan Hantel, Jyothis T George, Maximilian von Eynatten, Audrey Koitka-Weber, Christoph Wanner. Clin J Am Soc Nephrol 2020
7


Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Antonio Ceriello, Anne Pernille Ofstad, Isabella Zwiener, Stefan Kaspers, Jyothis George, Antonio Nicolucci. Cardiovasc Diabetol 2020
5


Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
João Pedro Ferreira, Subodh Verma, David Fitchett, Anne Pernille Ofstad, Sabine Lauer, Isabella Zwiener, Jyothis George, Christoph Wanner, Bernard Zinman, Silvio E Inzucchi. Cardiovasc Diabetol 2020
3